Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Programmed Death-ligand 1 (PD-L1)
100%
PD-L1 Expression
100%
PI3K-AKT-mTOR Pathway
100%
Lung Cancer
60%
Mammalian Target of Rapamycin (mTOR)
40%
Regulatory T Cells
20%
Clinical Benefit
20%
Genetically Engineered Mouse Models
20%
Tumor Growth
20%
Syngeneic
20%
Immunosuppression
20%
Tumor Microenvironment
20%
Immune Escape
20%
Squamous Cell Carcinoma (SqCC)
20%
Membrane Expression
20%
Oncogenic Signaling
20%
Immune Checkpoint
20%
Tumor-infiltrating T Cells
20%
Anti-PD-1 Antibody
20%
Human Lung Adenocarcinoma Cells
20%
Oncogenic Drivers
20%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Programmed Death-Ligand 1
100%
Mammalian Target of Rapamycin
100%
Lung Cancer
50%
Neoplasm
16%
In Vitro
16%
T Cell
16%
Epidermal Growth Factor Receptor
16%
Immunosuppressive Treatment
16%
Tumor Progression
16%
Tumor Microenvironment
16%
Squamous Cell Carcinoma
16%
Regulatory T Cell
16%
Lung Adenocarcinoma
16%
Biochemistry, Genetics and Molecular Biology
Mammalian Target of Rapamycin
100%
PD-L1
100%
T Cell
16%
Epidermal Growth Factor Receptor
16%
Tumor Progression
16%
Mouse Model
16%
KRAS
16%
Regulatory T Cell
16%
Syngenic
16%
Genetically Engineered Mouse Strain
16%
Immune Checkpoints
16%
Immunology and Microbiology
Programmed Death-Ligand 1
100%
Mouse Model
16%
T Cell
16%
Regulatory T Cell
16%
Squamous Cell
16%
Immunosuppression
16%
Syngenic
16%
Immune Escape
16%
Genetically Engineered Mouse Strain
16%